Tumour DNA Holds the Key to Classifying Hereditary Cancer Risk
A pivotal study published in *The Lancet* EBioMedicine demonstrates a novel strategy to improve the classification of germline BRCA1 and BRCA2 variants, a cornerstone of precision oncology and hereditary cancer risk assessment. By analyzing whole-genome sequencing data from multiple breast tumour datasets, researchers found that algorithms predicting homologous recombination deficiency (HRD) status can effectively distinguish the genomic profiles associated with pathogenic BRCA1 and BRCA2 mutations. This tumour-based approach provides high-weight evidence that can help resolve the uncertainty surrounding many variants of unknown significance (VUS), directly addressing a major challenge in cancer genomics. The integration of tumour sequencing data offers a powerful, complementary tool for more accurate germline variant interpretation, potentially guiding critical decisions in cancer prevention, targeted therapy, and genetic counselling.
Study Significance: For oncologists and geneticists, this work directly tackles the clinical ambiguity of BRCA VUS, which can stall preventive and therapeutic decisions. By leveraging the somatic mutational landscape of the tumour itself, this method adds a robust layer of functional evidence for variant classification. This advancement could significantly refine hereditary cancer risk models, optimize patient selection for PARP inhibitor therapies, and strengthen the framework for personalized cancer care based on both germline and somatic genomics.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
